Literature DB >> 20861812

Promoter hypermethylation in prostate cancer.

Jong Y Park1.   

Abstract

BACKGROUND: The prostate gland is the most common site of cancer and the second leading cause of cancer mortality in American men. It is well known that epigenetic alterations such as DNA methylation within the regulatory (promoter) regions of genes are associated with transcriptional silencing in cancer. Promoter hypermethylation of critical pathway genes could be potential biomarkers and therapeutic targets for prostate cancer.
METHODS: This review discusses current information on methylated genes associated with prostate cancer development and progression.
RESULTS: Over 30 genes have been investigated for promoter methylation in prostate cancer. These methylated genes are involved in critical pathways, such as DNA repair, metabolism, and invasion/metastasis. The role of hypermethylated genes in regulation of critical pathways in prostate cancer is reviewed.
CONCLUSIONS: These findings may provide new information of the pathogenesis of prostate cancer. Certain epigenetic alterations in prostate tumors are being translated into clinical practice for therapeutic use.

Entities:  

Mesh：

Year:  2010        PMID： 20861812      PMCID： PMC3167691          DOI： 10.1177/107327481001700405

Source DB:  PubMed          Journal:  Cancer Control        ISSN： 1073-2748            Impact factor:   3.302


  140 in total

1.  Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.

Authors:  Wenyong Chen; Timothy K Cooper; Cynthia A Zahnow; Michael Overholtzer; Zhiquan Zhao; Marc Ladanyi; Judith E Karp; Nalan Gokgoz; Jay S Wunder; Irene L Andrulis; Arnold J Levine; Joseph L Mankowski; Stephen B Baylin
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

2.  Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma.

Authors:  Yutaka Tokumaru; Susan V Harden; Dong-Il Sun; Keishi Yamashita; Jonathan I Epstein; David Sidransky
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

3.  Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer.

Authors:  Ozlem Topaloglu; Mohammad Obaidul Hoque; Yutaka Tokumaru; Juna Lee; Edward Ratovitski; David Sidransky; Chul-so Moon
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

4.  Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer.

Authors:  C Jerónimo; R Henrique; J Oliveira; F Lobo; I Pais; M R Teixeira; C Lopes
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

5.  Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.

Authors:  Rakesh Singal; Larry Ferdinand; Isildinha M Reis; James J Schlesselman
Journal:  Oncol Rep       Date:  2004-09       Impact factor: 3.906

Review 6.  DNA methylation in prostate cancer.

Authors:  Long-Cheng Li; Steven T Okino; Rajvir Dahiya
Journal:  Biochim Biophys Acta       Date:  2004-09-20

7.  Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene.

Authors:  Jingmei Zhang; Limin Liu; Gerd P Pfeifer
Journal:  Oncogene       Date:  2004-03-18       Impact factor: 9.867

8.  A survey of gene-specific methylation in human prostate cancer among black and white men.

Authors:  Karen Woodson; Jeffrey Hanson; Joseph Tangrea
Journal:  Cancer Lett       Date:  2004-03-18       Impact factor: 8.679

9.  Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.

Authors:  Xuegong Zhu; Irwin Leav; Yuet-Kin Leung; Mengchu Wu; Qin Liu; Ying Gao; John E McNeal; Shuk-Mei Ho
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

10.  Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation.

Authors:  A R Florl; C Steinhoff; M Müller; H-H Seifert; C Hader; R Engers; R Ackermann; W A Schulz
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640
View more
  27 in total

1.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.

Authors:  Hsiang-Yu Lin; Yi-Chiu Kuo; Yu-I Weng; I-Lu Lai; Tim H-M Huang; Shuan-Pei Lin; Dau-Ming Niu; Ching-Shih Chen
Journal:  Prostate       Date:  2012-04-26       Impact factor: 4.104

2.  Short AIP1 (ASK1-Interacting Protein-1) Isoform Localizes to the Mitochondria and Promotes Vascular Dysfunction.

Authors:  Zheng Li; Li Li; Haifeng Zhang; Huanjiao Jenny Zhou; Weidong Ji; Wang Min
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-17       Impact factor: 8.311

Review 3.  Global DNA hypomethylation in prostate cancer development and progression: a systematic review.

Authors:  R Zelic; V Fiano; C Grasso; D Zugna; A Pettersson; A Gillio-Tos; F Merletti; L Richiardi
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-11       Impact factor: 5.554

Review 4.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 5.  Interrogating genomic and epigenomic data to understand prostate cancer.

Authors:  Jung Kim; Jindan Yu
Journal:  Biochim Biophys Acta       Date:  2012-01-03

6.  Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer.

Authors:  Peng Zhang; Hui Wang; Jianming Wang; Qingzuo Liu; Yongqiang Wang; Fan Feng; Lei Shi
Journal:  Oncol Lett       Date:  2017-05-31       Impact factor: 2.967

Review 7.  Epigenetic mechanisms in commonly occurring cancers.

Authors:  Lauren P Blair; Qin Yan
Journal:  DNA Cell Biol       Date:  2012-04-20       Impact factor: 3.311

8.  Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.

Authors:  Kirill Litovkin; Steven Joniau; Evelyne Lerut; Annouschka Laenen; Olivier Gevaert; Martin Spahn; Burkhard Kneitz; Sofie Isebaert; Karin Haustermans; Monique Beullens; Aleyde Van Eynde; Mathieu Bollen
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-18       Impact factor: 4.553

9.  Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer.

Authors:  Bing Yang; Sachin Bhusari; Jessica Kueck; Pushpa Weeratunga; Jennifer Wagner; Glen Leverson; Wei Huang; David F Jarrard
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

10.  Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.

Authors:  Guangxun Li; Hong Wang; Anna B Liu; Connie Cheung; Kenneth R Reuhl; Maarten C Bosland; Chung S Yang
Journal:  Cancer Prev Res (Phila)       Date:  2012-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.